← All organizations
Highest phase reached
Phase 4
First clinical trial
Oct 1, 2000First marketed drug
Sep 12, 2003First NDA
Sep 12, 2003Last known activity
Sep 1, 2015
Acquired by Merck on Dec 8, 2014
Timeline
1990s
- Jan 1, 1992
Cubist— Founded
2000s
- Aug 8, 2000
TerraGen Discovery— Acquired
- Dec 26, 2007
Illumigen Biosciences— Acquired
- Dec 14, 2009
Calixa— Acquired
2010s
- Dec 12, 2011
Adolor Corp— Acquired
- Sep 11, 2013
Trius Therapeutics— Acquired
- Oct 24, 2013
Optimer Pharmaceuticals— Acquired
- Jun 20, 2014
tedizolid phosphate— NDA Organization
- Dec 8, 2014
Merck— Acquired By
- Dec 19, 2014
ceftolozane— NDA Secondary Org
Drugs by trial phase (44 distinct, 111 trials)
Phase 4 (8 own, 2 via acquisition)
Phase 3 (11 own, 4 via acquisition)
Phase 2 (13 own, 0 via acquisition)
Phase 1 (3 own, 2 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Approved for
Studied for
- Acute Pain
- Arthritis
- Arthritis, Rheumatoid
- Bacteremia
- Bacterial Infections
- Blood Loss, Surgical
- Cancer Pain
- Cellulitis
- Clostridium Infections
- Communicable Diseases
- Constipation
- Critical Illness
- Cystic Fibrosis
- Diabetic Foot
- Diarrhea
- Endocarditis
- Endocarditis, Bacterial
- End Stage Liver Disease
- Erysipelas
- Fallopian Tube Neoplasms
- Febrile Neutropenia
- Fibrosis
- Gastrointestinal Diseases
- Gram-Negative Bacterial Infections
- Gram-Positive Bacterial Infections
- Healthcare-Associated Pneumonia
- Hemorrhage
- Hepatitis
- Hepatitis A
- Hepatitis B
- Ileus
- Infections
- Intestinal Diseases
- Intraabdominal Infections
- Kidney Diseases
- Kidney Failure, Chronic
- Liver Diseases
- Lung Diseases
- Neuralgia
- Neuralgia, Postherpetic
- Neutropenia
- Osteoarthritis
- Osteoarthritis, Knee
- Osteomyelitis
- Peripheral Nervous System Diseases
- Pneumonia
- Pneumonia, Bacterial
- Pneumonia, Ventilator-Associated
- Pseudomonas Infections
- Pulmonary Fibrosis
- Pyelonephritis
- Renal Insufficiency
- Skin Diseases
- Skin Diseases, Bacterial
- Skin Diseases, Infectious
- Soft Tissue Infections
- Spinal Cord Injuries
- Staphylococcal Infections
- Staphylococcal Skin Infections
- Surgical Wound
- Surgical Wound Infection
- Urinary Tract Infections
- Wound Infection
- Wounds and Injuries
Marketed drugs (6)
Subsidiaries (6 direct, 6 total across the full acquisition tree)
Recent trials (50)
- NCT02421120CollaboratorPhase 4Sep 1, 2015
- NCT02276482Lead sponsorPhase 3Mar 25, 2015
- NCT02387372Lead sponsorPhase 1Feb 5, 2015
- NCT02341599Lead sponsorPhase 1Dec 1, 2014
- NCT02070757Lead sponsorPhase 3Sep 23, 2014
- NCT02266706Lead sponsorPhase 1Sep 17, 2014
- NCT02097953CollaboratorEarly Phase 1May 1, 2014
- NCT02355938CollaboratorPhase 4Feb 1, 2014
- NCT02019420Lead sponsorPhase 3Jan 6, 2014
- NCT02508740Lead sponsorPhase 1Sep 1, 2013
- NCT01922011Lead sponsorPhase 3Sep 1, 2013
- NCT01901328Lead sponsorPhase 3Aug 1, 2013
- NCT01901302Study directorPhase 3Jul 1, 2013
- NCT01901302Lead sponsorPhase 3Jul 1, 2013
- NCT01901341Lead sponsorPhase 3Jul 1, 2013
Details
- Founded
- Lexington, MA, US Jan 1, 1992
- First NDA
- Sep 12, 2003
- Last known activity
- Sep 1, 2015
Designations held
- Priority review